tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Lanford RE et al. Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia. 2003 Virology pmid:12832204
Stremlau M et al. Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. 2006 Virology pmid:16643975
Goldfeld AE et al. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. 1995 Virology pmid:7538254
Zhao W et al. Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. 2006 Virology pmid:16828834
Mistríková J et al. Increased neoplasm development due to immunosuppressive treatment with FK-506 in BALB/C mice persistently infected with the mouse herpesvirus (MHV-72). 1999 Viral Immunol. pmid:10532652
Gambarino S et al. Human Cytomegalovirus Impact on mir-146a Expression Levels in Kidney Transplant Patients. 2016 Viral Immunol. pmid:27077822
Shen ZY et al. Variations in the S and P regions of the hepatitis B virus genome under immunosuppression in vitro and in vivo. 2012 Viral Immunol. pmid:22946668
Mortola E et al. The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. 1998 Vet. Res. Commun. pmid:10066129
Tanaka Y et al. Suppression of feline coronavirus replication in vitro by cyclosporin A. 2012 Vet. Res. pmid:22546085
Kano R et al. Treatment of sterile panniculitis in a dog. 2004 Vet. Rec. pmid:15134169
Ofri R et al. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. 2009 Vet. J. pmid:17950639
Sestak K et al. Tacrolimus-FK506 induced immunosuppression in gnotobiotic piglets. 2000 Vet. Immunol. Immunopathol. pmid:11137126
Marsella R et al. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. 2004 Vet. Dermatol. pmid:15500481
Mauldin EA et al. Proliferative and necrotizing otitis externa in four cats. 2007 Vet. Dermatol. pmid:17845627
Banovic F et al. Tacrolimus therapy for dermal arteritis of the nasal philtrum refractory to surgery and anti-inflammatory therapy (doxycycline/niacinamide and topical fluocinolone) in a dog. 2018 Vet. Dermatol. pmid:28990239
Hilton H et al. Evaluation of four topical preparations for the treatment of cannon hyperkeratosis in a horse. 2008 Vet. Dermatol. pmid:19055613
Marsella R and Nicklin CF Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: a pilot study. 2002 Vet. Dermatol. pmid:12174182
Banovic F et al. Therapeutic effectiveness of calcineurin inhibitors in canine vesicular cutaneous lupus erythematosus. 2017 Vet. Dermatol. pmid:28439997
Rosenkrantz WS Pemphigus: current therapy. 2004 Vet. Dermatol. pmid:15030557
Olivry T et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. 2010 Vet. Dermatol. pmid:20456716
Marsella R et al. Investigation on the effects of topical therapy with 0.1% tacrolimus ointment (Protopic) on intradermal skin test reactivity in atopic dogs. 2004 Vet. Dermatol. pmid:15305928
Lehner GM and Linek M A case of vesicular cutaneous lupus erythematosus in a Border collie successfully treated with topical tacrolimus and nicotinamide-tetracycline. 2013 Vet. Dermatol. pmid:24118370
Kelley LS et al. Safety and tolerability of 0.1% tacrolimus solution applied to the external ear canals of atopic beagle dogs without otitis. 2010 Vet. Dermatol. pmid:20609208
Bensignor E and Olivry T Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. 2005 Vet. Dermatol. pmid:15725106
Scholz FM et al. Focal metatarsal fistulae syndrome affecting a greyhound dog successfully treated with topical 0.1% tacrolimus ointment. 2015 Vet. Dermatol. pmid:26216245
Nell B et al. The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. 2005 Jan-Feb Vet Ophthalmol pmid:15644099
Berdoulay A et al. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. 2005 Jul-Aug Vet Ophthalmol pmid:16008701
Hafizi S et al. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling. 2004 May-Jun Vascul. Pharmacol. pmid:15607500
Dissemond J et al. Successful treatment of stasis dermatitis with topical tacrolimus. 2004 VASA pmid:15623206
Woodward RS et al. The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine. 2011 Value Health pmid:21315636
Christ B et al. Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. 2001 Urology pmid:11597545
Harmon JD et al. Stuttering priapism in a liver transplant patient with toxic levels of fk506. 1999 Urology pmid:10754131
Chkhotua AB et al. Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols. 2003 Urology pmid:14665344
Ebert AK et al. [Topical therapy of balanitis xerotica obliterans in childhood. Long-term clinical results and an overview]. 2007 Urologe A pmid:17994212
[Tacrolimus--a new perspective in kidney transplantation]. 1996 Urologe A pmid:9022401
Nomura T et al. Enhancement by cyclosporin A of taxol-induced apoptosis of human urinary bladder cancer cells. 2002 Urol. Res. pmid:12086014
Hwang MT and Goldfarb DS Uric acid stones following hepatic transplantation. 2004 Urol. Res. pmid:15565437
Veroux P et al. Severe neurotoxicity in tacrolimus-treated living kidney transplantation in two cases. 2003 Urol. Int. pmid:14646448
Pichler R et al. De novo renal cell carcinoma in a kidney allograft with focus on contrast-enhanced ultrasound. 2014 Urol. Int. pmid:25115614
Naderi GH et al. Tacrolimus rescue therapy for corticosteroid-resistant and polyclonal antibody-resistant kidney allograft rejections. 2009 Urol J pmid:19241339
Freire A et al. Comparison of blood tacrolimus concentrations in liver and kidney transplant recipients using ACMIA and MEIA immunoassays. 2008 Ups. J. Med. Sci. pmid:18521804
Präst I et al. Nerve cells in transplanted pancreatic islets: no effects of cyclosporin or tacrolimus on immediate neuronal survival. 2001 Ups. J. Med. Sci. pmid:11888070
Valesky EM et al. [Postoperative pyoderma gangrenosum of Cullen]. 2007 Unfallchirurg pmid:17786400
Deleuran M et al. [Topical immune modulation and risk of cancer]. 2009 Ugeskr. Laeg. pmid:19732533
Rosenzweig M [Prescription of topical immunomodulators]. 2009 Ugeskr. Laeg. pmid:19732534
Thestrup-Pedersen K and Thomsen TF [Creams used in the treatment of children can cause cancer]. 2005 Ugeskr. Laeg. pmid:15832731
Tusgaard Petersen B et al. [Family occurrence of steroid-sensitive idiopathic nephrotic syndrome]. 2012 Ugeskr. Laeg. pmid:23153469
Mørtz CG and Deleuran MS [A case of childhood granulomatous perioral dermatitis (CGPD) in a three year old boy from Madagascar]. 2008 Ugeskr. Laeg. pmid:18252166
Tümgör G et al. Fatty liver due to high levels of serum tacrolimus after liver transplantation. 2007 Apr-Jun Turk. J. Pediatr. pmid:17907528
Ismailoglu O et al. Topical application of tacrolimus prevents epidural fibrosis in a rat postlaminectomy model: histopathological and ultrastructural analysis. 2011 Turk Neurosurg pmid:22194127
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790
Dinçkan A et al. Evaluation of the first 100 liver transplantations. 2008 Turk J Gastroenterol pmid:18386237
Bajetta E et al. Merkel cell carcinoma after liver transplantation: a case report. 2007 May-Jun Tumori pmid:17679476
Vennarecci G et al. [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. 2003 Jul-Aug Tumori pmid:12903579
Sommerer C et al. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. 2016 Trials pmid:26888217
Nashan B et al. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. 2015 Trials pmid:25873064
Snyder SH et al. Neural actions of immunophilin ligands. 1998 Trends Pharmacol. Sci. pmid:9509898
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Kunz J and Hall MN Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. 1993 Trends Biochem. Sci. pmid:7694398
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. 2003 Apr-May TreatmentUpdate pmid:17216847
Fredericks S et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. 2006 Transplantation pmid:16969296
Ogunseinde BA et al. A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant. 2003 Transplantation pmid:12883222
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Gralla J and Wiseman AC Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. 2009 Transplantation pmid:19502965
Leroy-Matheron C et al. Inhibitor against coagulation factor V after liver transplantation. 1999 Transplantation pmid:10532550
Lee D et al. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. 2017 Transplantation pmid:27779572
Hostettler KE et al. Cyclosporine A mediates fibroproliferation through epithelial cells. 2004 Transplantation pmid:15223908
Yang CW et al. Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. 2003 Transplantation pmid:12544865
Lykavieris P et al. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. 2003 Transplantation pmid:12544888
Naesens M et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. 2007 Transplantation pmid:17700162
Kato T et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. 2007 Transplantation pmid:17984834
Kiuchi T et al. A hepatic graft tuberculosis transmitted from a living-related donor. 1997 Transplantation pmid:9089234
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Jeske HC et al. Gemcitabine with cyclosporine or with tacrolimus exerts a synergistic effect and induces tolerance in the rat. 2003 Transplantation pmid:14557751
Muthukumar T et al. HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. 2013 Transplantation pmid:23503504
Thervet E et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. 2003 Transplantation pmid:14578760
Tabasco-Minguillan J et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. 1993 Transplantation pmid:7692637
Jain A et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. 2000 Transplantation pmid:10972220
Sharif A et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. 2010 Transplantation pmid:20145524
Wang SC et al. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. 1993 Transplantation pmid:7692640
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Gruber SA et al. Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. 2000 Transplantation pmid:10933170
Shapiro R et al. Alopecia as a consequence of tacrolimus therapy. 1998 Transplantation pmid:9603186
Fernandez LA et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. 1999 Transplantation pmid:10589951
Lang T et al. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. 1996 Transplantation pmid:8824477
Kandula P et al. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. 2012 Transplantation pmid:23037007
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Taylor-Fishwick DA et al. Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. 1993 Transplantation pmid:7689258
Vafadari R et al. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. 2012 Transplantation pmid:22960764
Opelz G and Döhler B Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. 2009 Transplantation pmid:19300179
Rostambeigi N et al. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. 2011 Transplantation pmid:21200364
Mikhalski D et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. 2008 Transplantation pmid:18401260
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Nankivell BJ et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. 2004 Transplantation pmid:15167607
Ciancio G et al. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. 2013 Transplantation pmid:23903014
Gruessner RW et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. 2008 Transplantation pmid:18192910
Komori K et al. The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. 2008 Transplantation pmid:18192920